Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Week 48 Efficacy Outcomes by Baseline Demographics in the Phase 2/3 PHOTON Trial

被引：0
作者：
Ghorayeb, Ghassan [1 ]
机构：
[1] West Virginia Univ, Eye Inst, Morgantown, WV USA
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2023年 / 64卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
2707
引用
收藏
页数：2
相关论文
共 50 条
[41]   Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema [J].
Scott, Ingrid U. ;
Bressler, Neil M. ;
Bressler, Susan B. ;
Browning, David J. ;
Chan, Clement K. ;
Danis, Ronald P. ;
Davis, Matthew D. ;
Kollman, Craig ;
Qin, Haijing .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2008, 28 (01) :36-40
[42]   Findings of the Phase 2 trial of the safety and efficacy of pegaptanib sodium (Macugen) in patients with diabetic macular edema [J].
Singerman, LJ .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46
[43]   Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial [J].
Wykoff, Charles C. ;
Brown, David M. ;
Reed, Kimberly ;
Berliner, Alyson J. ;
Gerstenblith, Adam T. ;
Breazna, Aurora ;
Abraham, Prema ;
Fein, Jordana G. ;
Chu, Karen W. ;
Clark, W. Lloyd ;
Leal, Sergio ;
Schmelter, Thomas ;
Hirshberg, Boaz ;
Yancopoulos, George D. ;
Vitti, Robert .
JAMA OPHTHALMOLOGY, 2023, 141 (09) :834-842
[44]   Additional visual and anatomic outcomes of intravitreal aflibercept injection 8 mg versus 2 mg: a post hoc analysis of the Phase 2 CANDELA study [J].
Fein, Jordana Goren .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
[45]   Evaluation of 8 mg Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration: Results from the Phase 2 CANDELA Study [J].
Brown, David M. .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
[46]   Relationship between Retinal Structural Abnormalities and Visual Outcomes in the Phase 2 Boulevard Trial for Diabetic Macular Edema [J].
Balasubramanian, Siva ;
Chen, Dinah ;
Yang, Qi ;
Kikuchi, Yusuke ;
Surulisamy, Kumar ;
Ruiz, Carlos .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
[47]   Vision and Diabetic Retinopathy Severity Score (DRSS) Following Intravitreal Aflibercept Injection (IAI) in Diabetic Macular Edema (DME) Patients with Hemoglobin A1c (HbA1c) Levels ≤8% and >8% at Baseline [J].
Brown, David M. .
DIABETES, 2014, 63 :A93-A93
[48]   Impact of Prior Therapy for Diabetic Macular Edema (DME) on Visual and Anatomic Outcomes Following Treatment with Intravitreal Aflibercept: Results from the Phase 3 VISTA-DME and VIVID-DME Studies [J].
Quan Dong Nguyen .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
[49]   Long-term efficacy and Safety of CT-P42 compared to Reference Aflibercept in Diabetic Macular Edema: 52-Week Results from the Phase 3 CT-P42 [J].
Stanga, Paulo-Eduardo ;
Wolf, Sebastian ;
Veselovsky, Milan ;
Veith, Miroslav ;
Papp, Andras ;
Mange, Shobhana ;
Mondal, Lakshikanta ;
Kim, Sunghyun ;
Ahn, Keumyoung ;
Kim, Suyoung ;
Son, Dain ;
Kang, Hyejin ;
Lee, Hyunjin ;
Brown, David M. ;
Stanga, Paulo-Eduardo ;
Wolf, Sebastian ;
Veselovsky, Milan ;
Veith, Miroslav ;
Papp, Andras ;
Mange, Shobhana ;
Mondal, Lakshikanta ;
Kim, Sunghyun ;
Ahn, Keumyoung ;
Kim, Suyoung ;
Son, Dain ;
Kang, Hyejin ;
Lee, Hyunjin ;
Brown, David M. .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
[50]   Visual and Anatomic Outcomes from VISTA and VIVID Studies of Intravitreal Aflibercept Injection (IAI) in Patients with Diabetic Macular Edema (DME): Effect of Baseline Hemoglobin A1c (HbA1c) Quartiles [J].
Singh, Rishi P. .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
12345